Perspectives
Analysis of the federal and state decisions shaping personalized medicine.
Compounding
The statement PHA issued on April 15, 2026, on FDA moving a group of peptide compounds toward formal advisory committee review. It names the substances involved and the expected timetable.
Perspective
New National Organization Focuses on Modern Policy, Patient Access, and Safe Innovation
Compounding
The announcement PHA issued on December 22, 2025, on a Texas ruling that narrowed the claims against a compounding pharmacy over compounded tirzepatide. PHA's lead strategic advisor led the defense.
Regenerative Medicine
The announcement PHA issued on December 12, 2025, setting out its case for a cGMP-based federal pathway for certain adult stem cell products. It carries statements from PHA's founder, president and lead strategic advisor.
Perspective
The launch announcement PHA issued on November 24, 2025, naming the coalition behind it and its founding focus on physician autonomy and patient access.
By priority
Advancing durable policy that supports responsible virtual care, continuity for patients, and clear rules for providers.
Engaging when state legislation, medical-board guidance, pharmacy-board policy, or other regulatory action may affect individualized care and independent clinical judgment.
Supporting appropriate quality and safety standards while preserving lawful access to patient-specific compounded therapies.
Advancing clear, responsible pathways for provider-directed regenerative care and patient access.
Addressing policy and regulatory issues that affect access to novel and individualized treatments as science and clinical practice evolve.
Supporting modern, evidence-based standards for individualized hormonal and metabolic care.
Exploring modern approaches to physician-led research, real-world evidence, registries, and other methods of generating evidence in personalized medicine.
